{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T18:38:43Z","timestamp":1789756723667,"version":"4.0.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jtct.2022.06.016","type":"journal-article","created":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T02:11:09Z","timestamp":1656123069000},"page":"619.e1-619.e8","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyun","family":"Moon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aastha","family":"Chandak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiji","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.06.016_bib0001","doi-asserted-by":"crossref","first-page":"e177","DOI":"10.1016\/j.bbmt.2020.04.013","article-title":"Current use of and trends in hematopoietic cell transplantation in the United States","volume":"26","author":"D'Souza","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.016_bib0002","doi-asserted-by":"crossref","DOI":"10.21926\/obm.transplant.1903081","article-title":"Viral infections in allogeneic hematopoietic stem cell transplant recipients: literature review","volume":"3","author":"Kodad","year":"2019","journal-title":"OBM Transplant"},{"key":"10.1016\/j.jtct.2022.06.016_bib0003","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1080\/17474086.2019.1562331","article-title":"Hematopoietic stem cell transplant with HLA-mismatched grafts: impact of donor, source, conditioning, and graft versus host disease prophylaxis","volume":"12","author":"Metheny","year":"2019","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtct.2022.06.016_bib0004","doi-asserted-by":"crossref","first-page":"e13396","DOI":"10.1111\/tid.13396","article-title":"Coinfection rates and clinical outcome data for cytomegalovirus and Epstein-Barr virus in post-transplant patients: a systematic review of the literature","volume":"22","author":"Anderson-Smits","year":"2020","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.jtct.2022.06.016_bib0005","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1182\/blood-2016-10-748426","article-title":"The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality","volume":"129","author":"Hill","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.016_bib0006","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.bbmt.2017.06.008","article-title":"Co-infections by double-stranded DNA viruses after ex vivo T cell-depleted, CD34+ selected hematopoietic cell transplantation","volume":"23","author":"Huang","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.016_bib0007","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jcyt.2014.02.010","article-title":"The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches","volume":"16","author":"Jain","year":"2014","journal-title":"Cytotherapy"},{"issue":"1 suppl","key":"10.1016\/j.jtct.2022.06.016_bib0008","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.bbmt.2008.10.005","article-title":"The burden of bacterial and viral infections in hematopoietic stem cell transplant","volume":"15","author":"Kontoyiannis","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.016_bib0009","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/j.bbmt.2017.06.017","article-title":"Real-world economic burden associated with transplantation-related complications","volume":"23","author":"Perales","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.016_bib0010","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1186\/s12879-017-2854-2","article-title":"Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients","volume":"17","author":"Robin","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jtct.2022.06.016_bib0011","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.bbmt.2009.06.019","article-title":"Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective","volume":"15","author":"Tomblyn","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.06.016_bib0012","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1200\/JCO.2017.73.0655","article-title":"Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cytomegalovirus, Epstein-Barr virus, and adenovirus infections after allogeneic hematopoietic stem-cell transplantation","volume":"35","author":"Tzannou","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.016_bib0013","doi-asserted-by":"crossref","DOI":"10.1172\/JCI133960","article-title":"CMV viral load kinetics as surrogate endpoints after allogeneic transplantation","volume":"131","author":"Duke","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2022.06.016_bib0014","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/cid\/cix804","article-title":"Kinetics of double-stranded DNA viremia after allogeneic hematopoietic cell transplantation","volume":"66","author":"Hill","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jtct.2022.06.016_bib0015","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/infdis\/jiaa237","article-title":"Adenovirus viral kinetics and mortality in ex vivo T cell-depleted hematopoietic cell transplant recipients with adenovirus infection from a single center","volume":"222","author":"Lee","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jtct.2022.06.016_bib0016","doi-asserted-by":"crossref","DOI":"10.1111\/petr.13084","article-title":"High human herpesvirus 6 viral load in pediatric allogeneic hematopoietic stem cell transplant patients is associated with detection in end organs and high mortality","volume":"22","author":"Winestone","year":"2018","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.jtct.2022.06.016_bib0017","series-title":"PREVYMISTM (letermovir) tablets [package insert]","year":"2022"},{"key":"10.1016\/j.jtct.2022.06.016_bib0018","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.06.016_bib0019","series-title":"Current use and outcome of hematopoietic stem cell transplantation: CIBMTR US summary slides","author":"Auletta","year":"2021"},{"key":"10.1016\/j.jtct.2022.06.016_bib0020","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1007\/s00277-019-03755-2","article-title":"Age-dependent determinants of infectious complications profile in children and adults after hematopoietic cell transplantation: lesson from the nationwide study","volume":"98","author":"Czy\u017cewski","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.06.016_bib0021","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/jpids\/piaa147","article-title":"BK virus epidemiology, risk factors, and clinical outcomes: an analysis of hematopoietic stem cell transplant patients at Texas Children's Hospital","volume":"10","author":"Ruderfer","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10.1016\/j.jtct.2022.06.016_bib0022","doi-asserted-by":"crossref","first-page":"505.e1","DOI":"10.1016\/j.jtct.2021.02.021","article-title":"Economic and clinical burden of virus-associated hemorrhagic cystitis in patients following allogeneic hematopoietic stem cell transplantation in the United States","volume":"27","author":"McGuirk","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.016_bib0023","unstructured":"Bentley TS, Ortner NJ. 2020 US organ and tissue transplants: cost estimates, discussion, and emerging issues. Available at: https:\/\/www.milliman.com\/en\/insight\/2020-us-organ-and-tissue-transplants. Accessed July 8, 2022."},{"key":"10.1016\/j.jtct.2022.06.016_bib0024","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2217\/ijh-2016-0001","article-title":"Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant","volume":"5","author":"Maziarz","year":"2016","journal-title":"Int J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.06.016_bib0025","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/10428194.2017.1375100","article-title":"Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma","volume":"59","author":"Maziarz","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.06.016_bib0026","doi-asserted-by":"crossref","first-page":"3786","DOI":"10.1002\/jmv.26462","article-title":"Cost-effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective","volume":"93","author":"Alsumali","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.jtct.2022.06.016_bib0027","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1182\/blood-2016-01-628982","article-title":"T cells for viral infections after allogeneic hematopoietic stem cell transplant","volume":"127","author":"Bollard","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.06.016_bib0028","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1111\/bjh.16423","article-title":"Epstein-Barr virus specific cytotoxic T lymphocytes for the treatment of severe Epstein-Barr virus mucocutaneous ulcer","volume":"189","author":"Khazal","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.06.016_bib0029","first-page":"5745","article-title":"Virus-specific T-cell therapy to treat BK polyomavirus infection in bone marrow and solid organ transplant recipients","volume":"4","author":"Nelson","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.016_bib0030","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.20.02608","article-title":"Third-party BK virus-specific cytotoxic T lymphocyte therapy for hemorrhagic cystitis following allotransplantation","volume":"39","author":"Olson","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.06.016_bib0031","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.jtct.2021.11.005","article-title":"Off-the-shelf third-party virus-specific T cell therapy to treat JC polyomavirus infection in hematopoietic stem cell transplantation recipients","volume":"28","author":"Rubinstein","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.jtct.2022.06.016_bib0032","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1182\/bloodadvances.2021004456","article-title":"Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted","volume":"5","author":"Rubinstein","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.06.016_bib0033","series-title":"Abstract presented at: ASH Annual Meeting and Exposition. December 11-14","article-title":"The impact of letermovir (LTV) prophylaxis on early cytomegalovirus infection (CMVi) and outcomes in the adult allogeneic hematopoietic cell transplantation (alloHCT) recipients with high-risk donor type","author":"Dadwal","year":"2021"},{"key":"10.1016\/j.jtct.2022.06.016_bib0034","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1111\/ajt.15764","article-title":"Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation","volume":"20","author":"Marty","year":"2020","journal-title":"Am J Transplant"},{"key":"10.1016\/j.jtct.2022.06.016_bib0035","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/iid3.431","article-title":"Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients","volume":"9","author":"Royston","year":"2021","journal-title":"Immun Inflamm Dis"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014075?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722014075?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:03:52Z","timestamp":1763003032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722014075"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2666636722014075"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.06.016","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical and Economic Burden of Multiple Double-Stranded DNA Viral Infections after Allogeneic Hematopoietic Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.06.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}